VIENNA, Va., April 4 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION
(Amex: CVM) announces that it has filed a provisional U.S. patent
application covering its drug CEL-1000 for the prevention/treatment of bird
flu and/or as an adjuvant to be included in a bird flu vaccine.
Geert Kersten, Chief Executive Officer of CEL-SCI said, "By filing this
patent in the U.S., we are preserving our rights to file patents on this
invention world-wide."
CEL-1000, when used as a single adjuvant (enhancer of a vaccine) or in
combination with other adjuvants, potentiates Th1 (cellular) and innate
(earliest stage) immune responses and protects animals from viral and
parasitic challenge. CEL-1000 provides antigen-independent (i.e.,
non-disease specific) and broad-spectrum protection upon challenge with the
disease causing agent(s), which is important against the bird flu virus
since it exhibits a high mutation rate.
CEL-1000, is a patented defined amino acid sequence derived from the
beta chain of human MHC-II, which itself is a modified version of a human
immune- based protein known to bind to both human and mouse immune cells
and appears to act by enhancing the host's protective immune response. It
is a defined peptide, which binds to the CD4 and/or likely a related
molecule LAG-3 on dendritic cells, macrophages and T cells, thereby
promoting the release of cytokines responsible for activating a protective
Th1 immune response (e.g., IL-12 and upon challenge IFN-gamma).
CEL-SCI Corporation is developing new immune system based treatments
for cancer and infectious diseases. The Company has operations in Vienna,
Virginia and Baltimore, Maryland.
When used in this report, the words "intends," "plans," "believes,"
"anticipated" and "expects" and similar expressions are intended to
identify forward-looking statements. Such statements are subject to risks
and uncertainties, which could cause actual results to differ materially
from those projected. The Company undertakes no obligation to publicly
release the result of any revision to these forward-looking statements,
which may be made to reflect the events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
CONTACT:
Gavin de Windt of CEL-SCI Corporation,
+1-703-506-9460; or Investor Relations: Mike Lucci of Lucci
Financial Group, LLC, +1-248-723-3330, for CEL-SCI Corporation
|
